Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06372865 PET Receptor Occupancy Study
NCT02138500Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of darigabat in epilepsy and anxiety disorder (3 cohorts), sponsored by Pfizer. Primary endpoints: GABAA Receptor Occupancy in the whole brain at Day 2 and Average plasma concentration of PF-06372865 at Day 2. Started May 2014; status: completed.
02
Drugs
darigabat
03
Conditions
epilepsyanxiety disorder
Beyond the preview
Go deeper on NCT02138500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138500.